NAD+ / MOTS-c / 5-Amino-1MQ groups a compounded coenzyme, a peptide with one recruiting human trial, and a small molecule with no human data of any kind, under one longevity-framed name. No two of the three have been tested together, and 5-Amino-1MQ’s oral capsule form means the three cannot actually share a single injectable vial the way the name implies. It is almost always sold as a bundle of separate products rather than one combined product.
Ask about NAD+ / MOTS-c / 5-amino-1MQ stack
Research snapshot
| Peptide category | Longevity-framed grouping of three unrelated compounds (coenzyme + peptide + small molecule) |
| Primary research interest | General longevity and mitochondrial support (as marketed; not established for any combination) |
| Highest available evidence | No study has tested any two of the three, let alone all three, together — each component carries its own separate, weak evidence base |
| Human research available | Not for the combination. Individually: NAD+ (compounded clinical use, no FDA label); MOTS-c (one recruiting Phase 2a trial); 5-Amino-1MQ (no human data of any kind) |
| Development status | Not a formulated drug product; a marketing bundle, usually of separate products (one oral, others injectable/infused) |
| Regulatory status | None of the three components FDA-approved for any indication |
Technical identity (composition)
| Primary name | NAD+ / MOTS-c / 5-Amino-1MQ |
| Alternative names | NAD MOTS-c 5-Amino-1MQ blend, NAD/MOTS-c/5-Amino-1MQ stack, “the longevity stack,” “the mitochondrial stack,” NAD MOTSc 1MQ |
| Composition | NAD+ (varies by product), MOTS-c (varies by product), 5-Amino-1MQ (varies by product, usually a separate oral capsule) — not standardised |
| Share of vial by mass | Not applicable — these are typically sold as separate products (one oral, one or two injectable/infused), not one shared vial |
| Peptide sequence | Not applicable — a multi-component grouping; see each component’s own entry |
| Molecular formula | Not applicable — a multi-component grouping of chemically unrelated substances |
| CAS Registry Number | Not applicable — a multi-component grouping, not a single registered substance |
| Chemical modifications | Not applicable at the grouping level; see each component’s own entry |
| Peptide class | Not a single class — spans a coenzyme (NAD+), a mitochondrial-derived peptide (MOTS-c), and a small-molecule NNMT inhibitor (5-Amino-1MQ) |
| Primary biological target | Multiple, unrelated — see each component’s own entry |
| Developer or originator | Not a formal pharmaceutical development program — a marketing grouping |
| Development status | Not in any clinical development pathway as a combination |
What it is
NAD+ / MOTS-c / 5-Amino-1MQ is a name applied to a longevity-framed grouping of three unrelated compounds: NAD+, a coenzyme compounded and sold as an infusion or injection; MOTS-c, a mitochondrial-derived peptide with a single recruiting Phase 2a human trial and otherwise no completed human study; and 5-Amino-1MQ, a small-molecule NNMT inhibitor with no published human data of any kind, sold as an oral capsule. None is FDA-approved. None has been given together with either of the others in any study located for this entry.
The name is worth reading carefully, because unlike Wolverine, GLOW or KLOW, which describe peptides that can genuinely share one reconstituted vial, this grouping cannot exist as a single injectable product in the way the name suggests. 5-Amino-1MQ is a small molecule sold and used as an oral capsule; NAD+ and MOTS-c are given by infusion or injection. A “blend” under this name is therefore almost always a bundle of separate products sold together as a stack or kit, one oral and one or two injectable, rather than one vial containing all three.
Potential benefits and research applications
General longevity and mitochondrial support, a name that bundles three separate hypotheses
What is being investigated: whether raising NAD+ availability, activating a mitochondrial-derived peptide pathway, and inhibiting NNMT together support cellular energy metabolism and slow aspects of aging. How the effect might occur: each compound is proposed to act on a different piece of the same broad mitochondrial-and-NAD+ metabolism story, but through unrelated, independently studied mechanisms. Evidence: each component has its own separate, and separately weak, evidence base, detailed in its own entry on this site. Strength: has not been established for any two of the three together, let alone all three; each is, at best, being investigated on its own. Limitation: no study, animal or human, has tested any pairing of these three compounds, so there is no basis for expecting their individually weak evidence bases to add up to something stronger when stacked.
What dosage information circulates?
Figures in this section summarize amounts and schedules reported in published research or circulating online. Their inclusion documents what is reported and does not establish that a regimen is verified, safe, effective, or appropriate. No study has tested any two of these three compounds together, let alone all three, at any dose.
| Reported use or research objective | Route reported | Amount reported | Frequency reported | Reported duration | Evidence or source category |
|---|---|---|---|---|---|
| NAD+ component | Intravenous or subcutaneous | Varies widely by clinic or vendor protocol | Varies | Varies | Community/vendor reported (compounded clinical use, no completed dose-ranging trial identified) |
| MOTS-c component | Subcutaneous | Low single-digit milligram range | Once daily to a few times weekly | Often cycled; no fixed length reported | Community/vendor reported — no completed human dosing trial exists to compare against |
| 5-Amino-1MQ component | Oral | 50 mg per capsule, 1 to 3 per day | Once to three times daily | Reported cycling of roughly 3–4 weeks on, 1–2 off | Community/vendor reported — no human data of any kind exists to compare against |
Each component circulates on its own schedule and route, and none of the protocols reviewed for this entry describes the three being titrated or monitored as one combined regimen — they read as three separate products discussed under one marketing name.
What is known about the combination
No study, animal or human, testing any two of these three compounds together, let alone all three, was located for this entry. A PubMed search for “NAD” and “MOTS-c” together returned two results, both unrelated psychiatric-biomarker papers that happen to measure NAD-pathway and MOTS-c proteins on the same panel; neither administers either compound to anyone, and neither is a study of a combination.
The closest thing to a documented link between any two of the three components is regulatory rather than scientific. An FDA warning letter to GenoGenix LLC, dated 20 January 2026, states that NAD+ and 5-Amino-1MQ “do not appear on the 503B bulks list” and cites the firm for compounding substances not on that list. That letter establishes that a single compounding facility was cited over both substances; it does not establish that the two were combined into one product, and it says nothing at all about MOTS-c. It is reported here as the only primary document connecting any two of these three names, not as evidence of a tested or even marketed three-way combination.
What the component evidence actually says
Each of the three has its own entry on this site, and each carries a distinct kind of weak evidence, not the same kind:
- NAD+ has no FDA label and no approved dose; everything sold as IV or injectable NAD+ is compounded. The GenoGenix warning letter cited above also documents a lot of NAD+ found with excessive bacterial endotoxin, adverse events in patients who received it, and a recall with one event elevated to FDA Class I.
- MOTS-c has a striking mouse literature and almost no human data. Its single registered human trial, a Phase 2a study in prediabetes and obesity, was still recruiting with no results posted at the time this entry was compiled. Every mechanistic and metabolic claim beyond that rests on mice or cultured cells.
- 5-Amino-1MQ has no human data of any kind, not limited, not thin, absent. No interventional trial, observational study or case report of the compound in a person has been located anywhere. Its efficacy record is entirely mice, and its pharmacokinetic record is entirely rats.
Stacking three compounds with three different, and differently weak, evidence bases does not average out to something stronger. It compounds the number of open questions rather than resolving any of them.
What is not known
Whether any two of these three, or all three, do anything together that none would do alone. No study has tested any pairing, let alone the full combination, in any species.
Whether the products actually sold under this name are typically one combined injectable, a bundle of separate products, or something else; no independent survey of how this name is packaged in the market was carried out for this entry, beyond noting that 5-Amino-1MQ’s oral form makes a single shared vial implausible for all three.
Whether NAD+ material compounded alongside 5-Amino-1MQ at the same facility, as the GenoGenix letter describes, carries the same sterility and endotoxin concerns documented for that facility’s NAD+ lots specifically, or whether that is a fact about one firm rather than about this pairing generally.
Everything already unknown about each component alone: NAD+’s unresolved 503A/503B compounding status, MOTS-c’s complete absence of any completed human dosing trial, and 5-Amino-1MQ’s complete absence of human data of any kind.
Regulatory status
None of the three compounds is FDA-approved for any indication. NAD+ sits in an unresolved compounding-eligibility position and was the subject of the GenoGenix LLC warning letter and a related product recall, one event of which was classified Class I. MOTS-c had its nomination for the FDA Category 2 compounding list withdrawn and was separately listed for discussion at the July 2026 Pharmacy Compounding Advisory Committee meeting. 5-Amino-1MQ has never been submitted as an investigational new drug application in the United States, and this entry does not assert a compounding-list status for it beyond what the GenoGenix letter itself states.
Frequently asked questions
What is NAD+ / MOTS-c / 5-Amino-1MQ?
It is a marketing name grouping three unrelated compounds: NAD+, a compounded coenzyme; MOTS-c, a peptide with one recruiting human trial; and 5-Amino-1MQ, a small molecule with no human data at all. It is not one molecule and usually not one product.
How does it work?
Each compound is proposed to act on a different piece of mitochondrial and NAD+ metabolism, but through separate, unrelated mechanisms that have never been tested together.
What dosage has been studied?
No study has tested any two of these three compounds together, let alone all three, at any dose. Each component’s own dosing evidence, where any exists, is detailed in its own entry.
What dosage commonly circulates online?
Each component circulates on its own separate schedule and route, one oral (5-Amino-1MQ) and the others injectable or infused, with no protocol titrating or monitoring the three as a single regimen.
Has it been studied in humans?
Not as a combination. A PubMed search for NAD and MOTS-c together returned only unrelated biomarker papers, and no study of any two of these three compounds given together, in any species, was located.
Can all three come in one vial?
No. 5-Amino-1MQ is a small molecule sold as an oral capsule; NAD+ and MOTS-c are given by infusion or injection. What is sold under this name is almost always a bundle of separate products, not one combined injectable.
What side effects have been reported?
None specific to this combination. An FDA warning letter documented an NAD+ lot from one compounding facility contaminated with bacterial endotoxin, causing patient harm and a Class I recall, at the same facility cited for compounding both NAD+ and 5-Amino-1MQ, though that does not establish the two were combined into one product.
Is it approved?
No. None of the three components is FDA-approved for any indication.
What remains unknown?
Whether any two of these three, or all three, do anything together that none would do alone; how products under this name are actually packaged and dosed; and everything already unknown about each component separately.
Bottom line
NAD+ / MOTS-c / 5-Amino-1MQ is a marketing bundle, not a tested combination. Its three components have three separately weak evidence bases, ranging from a compounded coenzyme with an active FDA warning letter to a small molecule with no human data of any kind, and no study has ever tested any two of them together. Stacking three unproven compounds under one longevity-framed name does not make any of them more established; it just multiplies the number of open questions a buyer is taking on at once.
What circulates E5
| Reported use | Route | Amount reported | Frequency | Reported length |
|---|---|---|---|---|
| NAD+ component | Intravenous or subcutaneous | Varies widely by clinic or vendor protocol | Varies | Varies |
| MOTS-c component | Subcutaneous | Low single-digit milligram range | Once daily to a few times weekly | Often cycled; no fixed length reported |
| 5-Amino-1MQ component | Oral | 50 mg per capsule, 1 to 3 per day | Once to three times daily | Reported cycling of roughly 3-4 weeks on, 1-2 off |
Each component circulates on its own schedule, by its own route, and none of the three protocols reviewed for this entry describes the three being titrated or monitored as one regimen; they read as three separate products discussed under one name.
The comparison this site's policy requires is unusually stark for two of the three components. MOTS-c has no completed human dosing trial of any kind, so its circulating figure is being compared against the complete absence of a studied human dose, not against a lower or higher one. 5-Amino-1MQ has no human data whatsoever, so the same is true there, and more categorically: there is no human trial arm of any size to compare its circulating capsule dose against.
NAD+ is the partial exception, in that infusion protocols exist in clinical use, but those are compounded clinic protocols rather than results from a completed, published dose-ranging trial, and this entry did not locate one to check the circulating figures against either.
Recorded as an observation about what is published elsewhere. No figure here is a dose, a protocol, or a recommendation, and nothing in this section is evidence that any amount is safe or effective.
Sources
Research area: Longevity and mitochondrial.
